Hematopoietic Stem Cell Transplantation-Pipeline Insights, 2016


#515139

60pages

DelveInsight

$ 1250

In Stock

Summary

Hematopoietic Stem Cell TransplantationPipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Hematopoietic Stem Cell Transplantation. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Hematopoietic Stem Cell Transplantation Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

Hematopoietic Stem Cell TransplantationPipeline Insights, 2015 Report covers the Hematopoietic Stem Cell Transplantation pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides Hematopoietic Stem Cell Transplantation related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for Hematopoietic Stem Cell Transplantation.

Scope

  • DelveInsight’s report provides a Hematopoietic Stem Cell Transplantation Landscape across the globe
  • The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information
  • Coverage of the Hematopoietic Stem Cell Transplantation pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Hematopoietic Stem Cell Transplantation and also provide company profiling
  • Pipeline products coverage based on various stages of development from NDA filings to discovery.
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy

  • Complete Pipeline intelligence and complete understanding over therapeutics development for Hematopoietic Stem Cell Transplantation
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
  • Track your competitors and develop strategic initiatives to support your drug development activities.
  • Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
  • Understand the market and choose right partners for in-licensing and out licensing for your valuable assets
  • Understand the factors behind failed/discontinued projects and move ahead without leaving any stone unturned

Table of Contents

Hematopoietic Stem Cell Transplantation Overview
Hematopoietic Stem Cell Transplantation Pipeline Therapeutics
Hematopoietic Stem Cell Transplantation Therapeutics under Development by Companies 
Hematopoietic Stem Cell Transplantation Late Stage Products (Filed and Phase III)
Comparative Analysis 
Hematopoietic Stem Cell Transplantation Mid Clinical Stage Products (Phase II)
Comparative Analysis 
Hematopoietic Stem Cell Transplantation Early Clinical Stage Products (Phase I and IND Filed)
Comparative Analysis 
Hematopoietic Stem Cell Transplantation Discovery and Pre-Clinical Stage Products 
Comparative Analysis 
Drug Candidate Profiles
Hematopoietic Stem Cell Transplantation – Therapeutics Assessment 
Assessment by Monotherapy Products 
Assessment by Combination Products 
Assessment by Route of Administration 
Assessment by Molecule Type 
Hematopoietic Stem Cell Transplantation – Discontinued Products 
Hematopoietic Stem Cell Transplantation – Dormant Products
Companies Involved in Therapeutics Development for Hematopoietic Stem Cell Transplantation

Appendix 
Methodology 
Contact Us 
Disclaimer

Number of Products under Development for Hematopoietic Stem Cell Transplantation, 2015
Number of Products under Development by Companies 
Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2015
Comparative Analysis Mid Clinical Stage Products (Phase II), 2015
Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2015
Comparative Analysis Discovery and Pre-Clinical Stage Products, 2015
Drug Candidates Profiles
Hematopoietic Stem Cell Transplantation Assessment by Monotherapy Products 
Hematopoietic Stem Cell Transplantation Assessment by Combination Products 
Hematopoietic Stem Cell Transplantation Assessment by Route of Administration 
Hematopoietic Stem Cell Transplantation Assessment by Stage and Route of Administration 
Hematopoietic Stem Cell Transplantation Assessment by Molecule Type 
Hematopoietic Stem Cell Transplantation Assessment by Stage and Molecule Type 
Hematopoietic Stem Cell Transplantation Therapeutics – Discontinued Products 
Hematopoietic Stem Cell Transplantation Therapeutics – Dormant Products
Products under Development by Companies, 2015

Number of Products under Development for Hematopoietic Stem Cell Transplantation, 2015
Late Clinical Stage Products (Filed and Phase III), 2015
Mid Clinical Stage Products (Phase II), 2015
Early Clinical Stage Products (Phase I and IND Filed), 2015
Discovery and Pre-Clinical Stage Products, 2015
Hematopoietic Stem Cell Transplantation Assessment by Monotherapy Products 
Hematopoietic Stem Cell Transplantation Assessment by Combination Products 
Hematopoietic Stem Cell Transplantation Assessment by Route of Administration 
Hematopoietic Stem Cell Transplantation Assessment by Stage and Route of Administration 
Hematopoietic Stem Cell Transplantation Assessment by Molecule Type 
Hematopoietic Stem Cell Transplantation Assessment by Stage and Molecule Type